Tissue and serum proteomic profiling for diagnostic and prognostic bladder cancer biomarkers

Expert Rev Proteomics. 2010 Dec;7(6):897-906. doi: 10.1586/epr.10.82.


A panel of biomarkers for the early detection of bladder cancer has not yet been identified. Many different molecules, including DNA, RNA or proteins have been reported but none have provided adequate sensitivity for a single-tier screening test or a test to replace cystoscopy. Therefore, multimarker panels are discussed at present to give a more-precise answer to the biomarker quest. Mass spectrometry or 2D gel-electrophoresis have evolved greatly within recent years and are capable of analyzing multiple proteins or peptides in parallel with high sensitivity and specificity. However, transmission of screening results from one laboratory to another is still the main pitfall of those methods; a fact that emphasizes the need for consistent and standardized procedures as suggested by the Human Proteome Organization (HUPO). In this article, recent results in screening approaches and other proteomic techniques used for biomarker evaluation in bladder cancer are discussed with a focus on serum and tissue biomarkers.

Publication types

  • Review

MeSH terms

  • Animals
  • Biomarkers, Tumor* / blood
  • Biomarkers, Tumor* / urine
  • Humans
  • Mass Spectrometry / methods
  • Prognosis
  • Protein Array Analysis
  • Proteome / chemistry*
  • Proteomics / methods
  • Two-Dimensional Difference Gel Electrophoresis
  • Urinary Bladder Neoplasms / chemistry*
  • Urinary Bladder Neoplasms / diagnosis


  • Biomarkers, Tumor
  • Proteome